The standard of care in locally advanced rectal cancer is neoadjuvant chemoradiation
(nCRT) followed by radical surgery. Response to nCRT varies among patients and …

Resistance becomes major clinical issue in cancer treatment, which strongly limits patients
to benefit from oncotherapy. Growing evidences have been indicative of the critical role of …

Significant progress in the development of new immunotherapies has led to successful
clinical trials for malignant melanoma and non-small cell lung cancer; however, for the …

Neoadjuvant radiation is standard of care for locally advanced rectal cancer. Response to
radiation is highly variable and directly linked with survival. However, there currently are no …

Radiation therapy remains one of the most effective cancer treatments. Nevertheless,
biology-driven personalized radiation therapy that enables treatment according to the …

Objective Radioresistance is a significant obstacle for effective treatment of colorectal cancer
(CRC). Recent studies have indicated that miR-185 inhibits proliferation, survival, and …

Radiotherapy is an important strategy for rectal cancer patient treatment. However, the
efficiency of radiation is usually poor, especially in patients with advanced stage rectal …

The aim of this study was to associate FGFR4 rs1966265 and rs351855 variants with
colorectal cancer (CRC) in a Mexican population and to perform in silico analysis. Genomic …

Deregulation of receptor tyrosine kinase (RTK)-signaling is frequently observed in many
human malignancies, making activated RTKs the promising therapeutic targets. In particular …

Even though distinctive advances in the field of esophageal cancer therapy have occurred
over the last few years, patients' survival rates remain poor. FGF8, FGF18, and FGFR4 have …